Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Bristol-Myers Squibb Company (BMY)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 92,972,640
  • Shares Outstanding, K 1,634,540
  • Annual Sales, $ 20,776 M
  • Annual Income, $ 1,007 M
  • 36-Month Beta 0.94
  • Price/Sales 4.46
  • Price/Cash Flow 16.09
  • Price/Book 7.17

Price Performance

See More
Period Period Low Period High Performance
1-Month
53.49 +5.69%
on 06/21/18
57.07 -0.93%
on 07/13/18
+2.90 (+5.41%)
since 06/19/18
3-Month
49.96 +13.17%
on 05/08/18
57.07 -0.93%
on 07/13/18
+4.93 (+9.55%)
since 04/19/18
52-Week
49.96 +13.17%
on 05/08/18
70.05 -19.29%
on 02/16/18
+1.47 (+2.67%)
since 07/19/17

Most Recent Stories

More News
Roche's Tecentriq Met Primary Goal in First-Line NSCLC Study

Roche's (RHHBY) late-stage lung cancer study on immuno-oncology drug, Tecentriq, meets its co-primary endpoint of progression-free survival (PFS).

MRK : 62.51 (-0.68%)
NVS : 80.80 (-0.20%)
RHHBY : 28.9100 (-1.13%)
BMY : 56.54 (-0.60%)
Bristol-Myers Squibb and Gritstone Oncology Announce Clinical Research Collaboration to Evaluate Novel Immunotherapy Approach in Advanced Solid Tumors

Bristol-Myers Squibb Company (NYSE: BMY) and Gritstone Oncology today announced that the companies have entered into a clinical trial collaboration to evaluate the safety and tolerability...

BMY : 56.54 (-0.60%)
Pfizer's Hemophilia B Gene Therapy Candidate Enters Phase III

Pfizer (PFE) initiates phase III program on a gene therapy treatment, fidanacogene elaparvovec, for patients with hemophilia B.

ONCE : 82.08 (-3.83%)
BMRN : 102.87 (+0.18%)
PFE : 37.36 (-0.80%)
BMY : 56.54 (-0.60%)
Pharma Stock Roundup: PFE to Split Into 3 Units, J&J to Pay $4.7B in Talc Lawsuit

Pfizer (PFE) is re-organizing its business into three new units, effective 2019. A St Louis jury orders J&J (JNJ) to pay $4.69 billion in a lawsuit related to its talc-based products.

CTIC : 2.27 (+0.44%)
AZN : 37.03 (-0.80%)
JNJ : 125.94 (-1.46%)
MRK : 62.51 (-0.68%)
ABBV : 89.95 (-4.71%)
PFE : 37.36 (-0.80%)
BMY : 56.54 (-0.60%)
Bristol-Myers' Combo Drugs Get FDA Nod for Colorectal Cancer

Bristol-Myers' (BMY) Opdivo in combination with its Yervoy received the FDA approval to treat patients with metastatic colorectal cancer (mCRC) that has progressed following treatment with fluoropyrimidine,...

MRK : 62.51 (-0.68%)
IONS : 45.84 (+2.34%)
CCXI : 12.30 (-1.28%)
BMY : 56.54 (-0.60%)
Clearside Biomedical Appoints Carol Hoang as Vice President, Medical Affairs

Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company dedicated to developing treatments that restore and preserve vision for people with serious eye diseases, today announced the appointment...

CVS : 66.14 (-2.59%)
CLSD : 9.99 (-3.66%)
NVS : 80.80 (-0.20%)
BMY : 56.54 (-0.60%)
Announcing Jeremy Levin, CEO of Ovid Therapeutics, as the Keynote Speaker for NY/NJ CEO 2018

Boston Biotech Conferences is hosting NY/NJ CEO, taking place November 13-14, 2018 at Apella at Alexandria Center in New York City. This peer-to-peer meeting provides an opportunity to find new partners...

OVID : 10.58 (-0.94%)
TEVA : 23.06 (-2.00%)
BMY : 56.54 (-0.60%)
Bristol-Myers Squibb's Opdivo(R) (nivolumab) + Low-Dose Yervoy(R) (ipilimumab) is the First Immuno-Oncology Combination Approved for MSI-H/dMMR mCRC Patients Who Progressed Following Treatment with a Fluoropyrimidine, Oxaliplatin and...

--In the CheckMate -142 trial, Opdivo + Yervoy demonstrated an overall response rate of 46% (95% CI: 35-58; n = 38/82)1

BMY : 56.54 (-0.60%)
Bristol-Myer Sqb (BMY) Crosses Pivot Point Resistance at $56.70

Shares of Bristol-Myer Sqb (NYSE:BMY) have bullishly opened above the pivot of $56.50 today and have reached the first resistance level of $56.70. Should the shares continue to rise, the resistance pivots...

BMY : 56.54 (-0.60%)
Exalenz Bioscience's Non-Invasive BreathID(R) Test to be Evaluated in Two Bristol-Myers Squibb Phase 2b Clinical Trials in Adult Patients with NASH

Studies will use BreathID C-methacetin breath test to evaluate patient response to therapy

BMY : 56.54 (-0.60%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 24% Buy with a Weakest short term outlook on maintaining the current direction.

Longer term, the trend strength is Minimum. Long term indicators are in flux.

The market is approaching overbought territory. Be watchful of a trend reversal.

See More Share

Trade BMY with:

Business Summary

Bristol-Myers Squibb is a differentiated company, led by their unique BioPharma strategy that leverages the reach and resources of a major pharma company paired with the entrepreneurial spirit and agility of a biotech firm. They work every day to deliver innovative medicines for patients with serious...

See More

Key Turning Points

2nd Resistance Point 57.37
1st Resistance Point 56.95
Last Price 56.54
1st Support Level 56.10
2nd Support Level 55.67

See More

52-Week High 70.05
Fibonacci 61.8% 62.38
Fibonacci 50% 60.01
Fibonacci 38.2% 57.63
Last Price 56.54
52-Week Low 49.96

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
New Chart Menu
Right-click anywhere on the chart to open the Interactive Chart menu.

Free Barchart Webinar